
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways (with roles)<br>---------------------------------------------------<br><br>This cluster is dominated by cell-cycle and proliferation genes, plus a few neuronal/brain-enriched genes.<br><br>**Cell cycle / mitosis / proliferation**<br><br>These are strongly indicative of actively cycling cells:<br><br>- **M-phase / mitotic spindle / kinetochore / chromosome segregation**<br>  - **TOP2A** ‚Äì DNA topoisomerase IIŒ±, classic G2/M and mitotic marker; hallmark of proliferating cells.<br>  - **CDK1** ‚Äì master G2/M cyclin-dependent kinase; essential for mitotic entry.<br>  - **MKI67** ‚Äì Ki-67, canonical proliferation marker expressed in all active phases of the cell cycle.<br>  - **CENPF, CENPU** ‚Äì centromere proteins; kinetochore assembly and chromosome segregation.<br>  - **NUF2, SPC24, SPC25, KNL1** ‚Äì core kinetochore complex components (NDC80 complex and associated); spindle‚Äìkinetochore attachment.<br>  - **KIF11, KIF14, KIF15, KIF20A, KIF24** ‚Äì mitotic kinesins; spindle assembly, chromosome movement, cytokinesis, and centriole regulation.<br>  - **ASPM** ‚Äì spindle pole protein; strongly associated with proliferating neural progenitors and microcephaly when mutated.<br>  - **NUSAP1** ‚Äì nucleolar and spindle-associated protein; stabilizes microtubules during mitosis.<br>  - **TK1** ‚Äì thymidine kinase 1; S-phase/DNA synthesis marker.<br>  - **PBK (TOPK)** ‚Äì mitotic kinase; enriched in proliferating cells.<br>  - **SHCBP1** ‚Äì involved in cytokinesis and mitotic progression.<br>  - **DIAPH3** ‚Äì actin/microtubule regulator; cytokinesis and spindle function.<br>  - **POC1A** ‚Äì centriole component; centrosome integrity.<br>  - **MND1** ‚Äì DNA recombination; more canonical in meiosis but often upregulated in highly proliferative states.<br><br>- **DNA replication / repair / chromatin**<br>  - **NEIL3** ‚Äì DNA glycosylase involved in base excision repair; enriched in proliferating neural progenitors.<br>  - **ASF1B** ‚Äì histone chaperone; S-phase chromatin assembly.<br>  - **HIST1H1B** ‚Äì linker histone H1; chromatin compaction, often up in cycling cells.<br>  - **E2F8** ‚Äì E2F family transcription factor; drives S-phase entry and cell cycle gene expression.<br>  - **ESCO2** ‚Äì establishment of sister chromatid cohesion during S phase.<br>  - **NCAPG** ‚Äì condensin complex subunit; chromosome condensation.<br>  - **RDM1** ‚Äì DNA damage response protein.<br><br>- **General proliferation / cell-cycle transcriptional program**<br>  - **HMMR (RHAMM)** ‚Äì hyaluronan-mediated motility receptor; often upregulated in proliferating progenitors and cancers.<br>  - **MXD3** ‚Äì MYC network transcription factor; promotes proliferation in neural progenitors and tumors.<br>  - **ZNF367** ‚Äì zinc finger TF associated with cell cycle and proliferation.<br>  - **FAM111B** ‚Äì serine protease-like protein; linked to proliferative states.<br>  - **TMPO-AS1** ‚Äì lncRNA associated with proliferative/cancer cell states.<br>  - **FBXO43** ‚Äì F-box protein; cell cycle regulation (especially meiosis, but also seen in high-proliferation contexts).<br><br>**DNA/RNA editing and stress**<br><br>- **APOBEC3B** ‚Äì cytidine deaminase; DNA/RNA editing, often upregulated in proliferative or stressed cells (including tumors).<br><br>**Neuronal / brain-related functional markers**<br><br>- **CAMK2N2** ‚Äì endogenous inhibitor of CaMKII; enriched in neurons, especially excitatory cortical neurons.<br>- **DRAXIN** ‚Äì axon guidance cue; expressed in developing brain, particularly in commissural axon guidance.<br>- **CNIH2** ‚Äì AMPA receptor auxiliary subunit; strongly enriched in glutamatergic neurons.<br>- **CLGN (calmegin)** ‚Äì ER chaperone; in brain, associated with synaptic protein processing; also testis-enriched but appears in neuronal ER chaperone programs.<br>- **NMU (neuromedin U)** ‚Äì neuropeptide; expressed in specific neuronal populations (hypothalamus, brainstem, some cortical interneurons in some datasets).<br><br>**Other / less specific**<br><br>- **XKR5** ‚Äì XK-related protein; limited functional annotation, sometimes seen in brain.<br>- **HUNK** ‚Äì serine/threonine kinase; expressed in brain and other tissues.<br>- **RIBC2, C21orf58, ATP8B3, LKAAEAR1, AC016205.1, AL359513.1** ‚Äì poorly characterized or lncRNA/ORFs; not strongly cell-type defining.<br><br>Overall functional picture: a strongly proliferative, mitotic population with a clear neuronal/brain transcriptional context (CAMK2N2, CNIH2, DRAXIN, CLGN, NMU), consistent with **dividing neural progenitors / cycling neural precursors** rather than glia or non-neural contaminants.<br><br>---<br><br>2. Key cell-type‚Äìinformative markers (with roles)<br>-------------------------------------------------<br><br>Focusing on markers that help distinguish major brain cell classes:<br><br>**Neuronal / excitatory lineage markers**<br><br>- **CAMK2N2** ‚Äì highly enriched in excitatory neurons (cortical pyramidal neurons) and their lineage; inhibitor of CaMKII, which is central to glutamatergic synaptic plasticity.<br>- **CNIH2** ‚Äì AMPA receptor auxiliary subunit; strongly associated with glutamatergic synapses; robust marker of excitatory neurons in human/mouse cortex scRNA-seq atlases.<br>- **DRAXIN** ‚Äì developmental axon guidance molecule; expressed in developing neurons and neural progenitors, especially in corticogenesis and commissural tracts.<br>- **CLGN** ‚Äì ER chaperone; in brain, associated with synaptic protein folding/trafficking; appears in neuronal ER chaperone modules.<br>- **NMU** ‚Äì neuropeptide; in brain, marks specific neuronal subpopulations (e.g., hypothalamic, brainstem, and some cortical interneuron subsets).<br><br>These point toward a **neuronal lineage**, more specifically **glutamatergic/excitatory** rather than inhibitory, given CNIH2 and CAMK2N2.<br><br>**Progenitor / cycling markers with neural bias**<br><br>- **ASPM, NEIL3, HMMR, MXD3** ‚Äì repeatedly reported as markers of **neural progenitor cells (NPCs)** and **radial glia** in human fetal cortex and glioma scRNA-seq datasets.<br>- **TOP2A, MKI67, CDK1, NUSAP1, KIF11, CENPF, etc.** ‚Äì generic cycling markers, but in brain scRNA-seq they define **cycling NPCs / cycling glia / cycling endothelial** clusters depending on co-expression. Here, co-expression with neuronal markers (CNIH2, CAMK2N2, DRAXIN) strongly biases toward **cycling neuronal progenitors**.<br><br>**Absence of strong glial or non-neural markers**<br><br>- No astrocyte markers: e.g., **GFAP, AQP4, SLC1A3, ALDH1L1** are absent.<br>- No oligodendrocyte lineage markers: **PDGFRA, OLIG1/2, SOX10, MBP, PLP1** are absent.<br>- No microglial markers: **CX3CR1, P2RY12, AIF1, CSF1R** are absent.<br>- No endothelial/pericyte markers: **PECAM1, VWF, KDR, PDGFRB, RGS5** are absent.<br><br>This pattern is typical of **neuronal progenitors / intermediate progenitor cells (IPCs)** rather than glial or vascular lineages.<br><br>---<br><br>3. Cross-referencing with scRNA-seq atlases and literature<br>----------------------------------------------------------<br><br>Using known human brain scRNA-seq references:<br><br>- **Human fetal cortex (e.g., Nowakowski et al. 2017; Polioudakis et al. 2019; Bhaduri et al. 2021)**:<br>  - Clusters annotated as **‚Äúcycling progenitors‚Äù**, **‚ÄúRG-div‚Äù**, **‚ÄúIPC-div‚Äù**, or **‚Äúproliferating excitatory neurons‚Äù** show:<br>    - Strong expression of **TOP2A, MKI67, CDK1, CENPF, NUSAP1, KIF11, ASPM, NEIL3, HMMR, PBK, NCAPG, ESCO2**.<br>    - Co-expression of neuronal lineage markers such as **CNIH2, CAMK2N2, DRAXIN** in excitatory-lineage cycling progenitors.<br>  - **ASPM, NEIL3, HMMR, MXD3** are canonical markers of **outer radial glia (oRG)** and **cycling intermediate progenitors** in human cortex.<br><br>- **Adult human brain / glioma scRNA-seq (e.g., Tirosh et al. 2016; Neftel et al. 2019)**:<br>  - ‚Äú**Proliferative neural progenitor-like**‚Äù or ‚Äú**cycling NPC-like**‚Äù malignant cells show a very similar gene set: **TOP2A, MKI67, CDK1, NUSAP1, CENPF, KIF11, ASPM, NEIL3, HMMR, PBK, NCAPG, ESCO2, E2F8**.<br>  - When these appear in non-malignant developmental datasets, they annotate as **cycling NPCs / IPCs**.<br><br>- **Adult human cortical neuron atlases (e.g., Hodge et al. 2019; Yao et al. 2021)**:<br>  - **CNIH2** and **CAMK2N2** are robust markers of **glutamatergic excitatory neurons** and their lineage.<br>  - These genes are not expressed in glia or endothelial cells at comparable levels.<br><br>Thus, the combination of:<br>- A very strong **cell-cycle/proliferation module**, and<br>- Clear **excitatory neuronal-lineage markers (CNIH2, CAMK2N2, DRAXIN, CLGN)**<br><br>matches best with **cycling excitatory neuronal progenitors / intermediate progenitors** in human brain atlases.<br><br>---<br><br>4. Most probable general cell type<br>----------------------------------<br><br>Given:<br><br>- Strong, broad **G2/M and S-phase signature** (TOP2A, MKI67, CDK1, ASPM, NUSAP1, CENPF, KIF11, etc.).<br>- Co-expression of **neuronal/excitatory markers** (CNIH2, CAMK2N2, DRAXIN, CLGN, NMU).<br>- Absence of canonical astrocyte, oligodendrocyte, microglial, or endothelial markers.<br><br>The most probable **general cell type** is:<br><br>> **Cycling neural progenitor / proliferating neuronal precursor (excitatory lineage)**<br><br>In many human brain scRNA-seq annotations, this would fall under ‚Äú**Neural progenitor cells (NPCs)**‚Äù or ‚Äú**Intermediate progenitor cells (IPCs)**‚Äù with a ‚Äú**dividing / cycling**‚Äù qualifier.<br><br>---<br><br>5. Top 3 most probable sub-cell types (ranked)<br>----------------------------------------------<br><br>Within the general category of neural progenitors / neuronal precursors, the likely subtypes are:<br><br>### 1) Cycling intermediate progenitor cells (IPC-div / ExN-div) ‚Äì **most likely**<br><br>**Rationale:**<br><br>- Strong mitotic signature (TOP2A, MKI67, CDK1, ASPM, NUSAP1, KIF11, CENPF, etc.) typical of **IPC-div** clusters in fetal cortex.<br>- Presence of **excitatory neuron‚Äìassociated genes** (CNIH2, CAMK2N2, DRAXIN, CLGN) suggests commitment toward **glutamatergic excitatory neurons** rather than multipotent radial glia.<br>- IPC-div clusters in human fetal cortex atlases often show:<br>  - High **ASPM, NEIL3, HMMR, MXD3, PBK, NCAPG, ESCO2, E2F8**.<br>  - Co-expression of early neuronal genes and synaptic machinery components, similar to what is seen here.<br><br>Thus, the best match is:<br><br>> **Subcell type 1 (most likely): Cycling intermediate progenitor cells (dividing excitatory IPCs / ExN-div)**<br><br>---<br><br>### 2) Cycling radial glia / neural stem cells (RG-div / oRG-div) ‚Äì **second most likely**<br><br>**Rationale:**<br><br>- **ASPM, NEIL3, HMMR, MXD3** are also strong markers of **radial glia**, especially **outer radial glia (oRG)**, which are highly proliferative in human cortex.<br>- Some RG-div clusters can express early neuronal genes as they transition toward IPCs.<br>- However, the presence of **CNIH2 and CAMK2N2**, which are more characteristic of committed excitatory neurons/lineage, slightly favors IPCs over RG.<br><br>So a plausible alternative annotation is:<br><br>> **Subcell type 2: Cycling radial glia / proliferative neural stem cells (RG-div / oRG-div)**<br><br>---<br><br>### 3) Proliferating excitatory neurons (early postmitotic but still cycling) ‚Äì **third most likely**<br><br>**Rationale:**<br><br>- Some datasets annotate a small population of **‚ÄúExN-div‚Äù** or **‚Äúproliferating excitatory neurons‚Äù**, where cells already express a relatively mature excitatory neuronal program but still show strong cell-cycle signatures.<br>- The presence of **CNIH2, CAMK2N2, NMU** could fit such a state.<br>- However, the very strong mitotic/progenitor signature and lack of more mature neuronal markers (e.g., NEUROD6, TBR1, SATB2, SLC17A7, GRIN1, etc.) argue that these are **earlier progenitors** rather than bona fide neurons.<br><br>Thus, a less likely but possible subtype:<br><br>> **Subcell type 3: Proliferating excitatory neuron precursors / early excitatory neurons (ExN-div)**<br><br>---<br><br>**Most likely subtype (final choice)**<br><br>Integrating all markers and atlas comparisons, the most consistent and specific annotation is:<br><br>> **Most likely subtype: Cycling intermediate progenitor cells (dividing excitatory neuronal progenitors; IPC-div / ExN-div)**<br><br>---<br><br>6. Concise summary<br>------------------<br><br>- The marker list is dominated by **cell-cycle and mitotic genes** (TOP2A, MKI67, CDK1, ASPM, NUSAP1, CENPF, KIF11, etc.), indicating a strongly **proliferative, cycling population**.<br>- Co-expression of **neuronal/excitatory markers** (CNIH2, CAMK2N2, DRAXIN, CLGN, NMU) and absence of glial/endothelial markers place these cells firmly in the **neuronal, specifically excitatory, lineage**.<br>- Cross-referencing human brain scRNA-seq atlases, this profile matches **dividing intermediate progenitor cells** (IPC-div / ExN-div) in developing cortex or analogous proliferative excitatory progenitors in other brain regions.<br>- Alternative but less likely interpretations are **cycling radial glia (RG-div)** or **proliferating excitatory neurons (ExN-div)**.<br><br>**Final annotation:**  <br>**Cycling excitatory neuronal progenitors ‚Äì dividing intermediate progenitor cells (IPC-div / ExN-div).**<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Cycling neural progenitors / proliferating neuronal precursors (excitatory lineage)</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Cycling intermediate progenitor cells (dividing excitatory IPCs / ExN-div)</li><li>Cycling radial glia / proliferative neural stem cells (RG-div / oRG-div)</li><li>Proliferating excitatory neuron precursors / early excitatory neurons (ExN-div)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    